Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCT200 in Patients With Advanced Squamous Non-small Cell Lung Cancer
NCT03808701Phase 1Unknown
- Sponsor
- Sinocelltech Group Limited
- Start
- Mar 2019
- Primary completion
- Dec 2019
- Modality
- Monoclonal Antibodies
01
Overview
Phase 1, open-label trial of sct200 in squamous cell carcinoma of the lung (SCCL) (2 arms), sponsored by Sinocelltech Group Limited. Primary endpoint: Objective Response Rate at 1 year. Status: unknown.
02
Drugs
sct200
03
Conditions
squamous cell carcinoma of the lung (SCCL)
Beyond the preview
Go deeper on NCT03808701.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03808701.